Your browser doesn't support javascript.
SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects.
Li, Shiqin; Li, Sijia; Disoma, Cyrollah; Zheng, Rong; Zhou, Mei; Razzaq, Aroona; Liu, Pinjia; Zhou, Yuzheng; Dong, Zijun; Du, Ashuai; Peng, Jian; Hu, Liqiang; Huang, Jufang; Feng, Pinghui; Jiang, Taijiao; Xia, Zanxian.
  • Li S; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Li S; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Disoma C; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Zheng R; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Zhou M; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Razzaq A; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Liu P; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Zhou Y; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Dong Z; Section of Infection and Immunity, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, USA.
  • Du A; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Peng J; Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
  • Hu L; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
  • Huang J; The First Hospital of Changsha, University of South China, Changsha, China.
  • Feng P; Department of Anatomy and Neurobiology, School of Basic Medical Sciences, Central South University, Changsha, China.
  • Jiang T; School of Life Sciences, Central South University, Changsha, China.
  • Xia Z; Section of Infection and Immunity, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, USA.
Rev Med Virol ; 31(2): e2168, 2021 03.
Article in English | MEDLINE | ID: covidwho-763331
ABSTRACT
The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally to over 200 countries with more than 23 million confirmed cases and at least 800,000 fatalities as of 23 August 2020. Declared a pandemic on March 11 by World Health Organization, the disease caused by SARS-CoV-2 infection, called coronavirus disease 2019 (COVID-19), has become a global public health crisis that challenged all national healthcare systems. This review summarized the current knowledge about virologic and pathogenic characteristics of SARS-CoV-2 with emphasis on potential immunomodulatory mechanism and drug development. With multiple emerging technologies and cross-disciplinary approaches proving to be crucial in our global response against COVID-19, the application of PROteolysis TArgeting Chimeras strategy, CRISPR-Cas9 gene editing technology, and Single-Nucleotide-Specific Programmable Riboregulators technology in developing antiviral drugs and detecting infectious diseases are proposed here. We also discussed the available but still limited epidemiology of COVID-19 as well as the ongoing efforts on vaccine development. In brief, we conducted an in-depth analysis of the pathogenesis of SARS-CoV-2 and reviewed the therapeutic options for COVID-19. We also proposed key research directions in the future that may help uncover more underlying molecular mechanisms governing the pathology of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Rev Med Virol Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: Rmv.2168

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Rev Med Virol Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: Rmv.2168